tbuckley/cabot-search huggingface dataset:
Treasurer's Report for Financial Year (FY) 2013
Authors: A. McLysaght
Journal: Molecular Biology and Evolution (2014)

Society’s total assets as of May 31, 2014, are as follows: $2,933,887.35

• Cash accounts (community checking + money market business): $2,749,480.42

• Total CDs: $184,406.93

This report covers the period of June 1, 2013–May 31, 2014. Due to the ongoing success of Molecular Biology and Evolution (MBE) and Genome Biology and Evolution (GBE), whose revenues continue to increase, the society remains in outstanding financial health. Society membership decreased marginally during financial year 2013: Membership-only subscriptions decreased from 732 in 2012 to 332 in 2013, whereas Society membership + journal subscriptions increased from 313 in 2012 to 687 in 2013.

The society used its income to publish its two journals, MBE and GBE, and to support its annual meeting, in 2013, held in Chicago, IL. This included providing increased graduate and postdoctoral travel awards, funding the Walter Fitch Prize Symposium (a cash prize for the winner and travel funds for all eight contestants), running the Undergraduate Diversity Mentoring Program (UDMP), subsidizing the provision of on-site childcare, supporting the travel and accommodation of Council members, and providing travel incentives for associate editors of MBE and GBE. We also supported three satellite meetings on important, focused and timely topics related to molecular evolutionary biology.


We continue to receive an annual donation of $2,000USD from Masatoshi Nei to support an honorarium for publication in MBE of the annual Nei Lecture given by the President of Society for MBE (SMBE) during the annual meeting. The 2013 Nei Lecture is to be the first lecture published under this scheme. The total value of the honorarium is to be $4,000USD. 


	Expense Category	June 1, 2013– May 31, 2014 (USD)
Interest income	532.23	
OUP signing bonus (new contract negotiation)	125,000.00	
OUP journal revenue (MBE)	585,510.00	
OUP journal revenue (GBE)	131,224.00	
Society fees collected by OUP	9,817.00	
Annual meeting reimbursement	0.00	
Nei Lecture fund donation (Masatoshi Nei)	2,000.00	
Total inflows	854,083.23	
2013 annual meeting	146,120.00	
SMBE satellite meetings	54,796.50	
Support for diversity programs (e.g., UDMP, childcare subsidy)	27,685.84	
Nei Lecture publication honorarium	0.00	
Bank charges	295.00	
Accounting	1,750.00	
Consultancy and professional society management	3,620.00	
Corporation fee	40.00	
Fitch prize	1,500.00	
SMBE council and editors-in-chief travel	26,915.29	
MBE/GBE associate editors travel incentive	110,001.07	
SMBE travel awards (Fitch, graduate, postdoc)	46,969.00	
SMBE website maintenance	514.81	
SMBE treasurer expenses	0.00	
MBE editorial office expenses	65,356.66	
MBE editor expenses	66,000.00	
MBE highlights and press releases	6,370.00	
GBE editor expenses	0.00	
GBE “Highlight” honoraria	10,090.50	
Postage	0.00	
Total outflows	568,024.67	
Overall total	286,058.56	


View it in a separate window
Prognostic Value of the Novel Mucosal Associated Lymphoid Tissue Prognostic Index (MALT-IPI) in Marginal Zone Lymphoma (MZL) Cases
Authors: Hian Li Esther Chan, Liang Piu Koh, Vanessa CL Chong, Xin Liu, Sanjay De Mel, Joanne Shu Xian Lee, Anand Jeyasekharan, Suk Teng Chin, Soon Thye Lim, Miriam Tao, Richard Quek, Mohamad Farid, Yuh Shan Lee, Daryl Tan, Chandramouli Nagarajan, Nicholas Francis Grigoropoulos, Colin Phipps Diong, Yeow Tee Goh, Tiffany Tang, Yen-Lin Chee, Michelle Poon
Journal: Blood (2018)
Abstract B07: CTC and CTM detection in sarcoma patients
Authors: Alexcia C. Braun, Celso A L Mello, Marcelo P. Corassa, Alves S. Vanessa, Emne A. Abdallah, Nicolau R. Ulisses, Mônica T. M. Díaz, Bianca T. C. P. Flores, Marcelo F. Fanelli, Patrizia Paterlini-Brechót, Ludmilla T. D. Chinen
Journal: Clinical Cancer Research (2018)

Abstract Background: Sarcomas represent 1% of all cancers in adults, 8% in adolescents and young people, and 10% in children. Even though it is a rare cancer, it contributes to a significant loss of years of life in comparison with other types of cancer (Amankwah et al., 2013). The presence of isolated circulating tumor cells (CTCs) or circulating tumor microemboli (CTM) in the blood of patients with sarcoma may be early markers of tumor invasion, because it is known that these cells circulate in the blood for months or years before the development of metastases (Paterlini-Brechot and Benali, 2007; Klain, 2009; Rhim et al., 2012). Objective: To isolate and quantify CTCs and CTM from sarcoma patients, evaluating their presence and correlation with progression-free survival (PFS). Methods: Blood (approximately 8 mL) was prospectively collected from patients with different types of high-degree sarcoma. Blood was collected before the beginning of chemotherapy. The samples were processed and filtered on ISET (Isolation by Size of Epithelial Tumor Cells, Rarecells, France) system for the isolation and quantification of CTCs and CTMs. Immunocytochemistry (ICC) was later performed with anti-CD45 antibody and counterstained with hematoxylin-eosyn for leucocytes population exclusion. The cutoff was estimated using the maximum of the standardized log-rank statistic proposed by Lausen and Schumacher (1992). Results: We analyzed 11 high-degree sarcoma patients after metastasis diagnosis, before the beginning of treatment. The median age was 53 years (18-77) and 54.5% were male. The median CTCs number was 2.0 CTCs/mL (1.0-11.0) at baseline. By Kaplan-Meier test, we observed that patients with CTC number below the established cutoff (4.5 CTCs/mL) had better PFS compared to those above the cutoff (7.4 vs. 1.0 months, respectively; P= 0.006). Moreover, patients without CTM had also better PFS compared to those patients with the presence of CTM (7.6 vs. 2.7 months, respectively; P= 0.13). Conclusion: This is the first study to demonstrate, besides the CTC and CTM presence in sarcoma patients, its real prognostic value, even in a limited sample. Our next step is to characterize these cells to better understand its capability to promote tumor progression. Citation Format: Alexcia C. Braun, Celso A L Mello, Marcelo P. Corassa, Alves S. Vanessa, Emne A. Abdallah, Nicolau R. Ulisses, Mônica T. M. Díaz, Bianca T. C. P. Flores, Marcelo F. Fanelli, Patrizia Paterlini-Brechót, Ludmilla T. D. Chinen. CTC and CTM detection in sarcoma patients [abstract]. In: Proceedings of the AACR International Conference held in cooperation with the Latin American Cooperative Oncology Group (LACOG) on Translational Cancer Medicine; May 4-6, 2017; São Paulo, Brazil. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(1_Suppl):Abstract nr B07.
Re: Sun et al.: Determining subclinical edema in Fuchs endothelial corneal dystrophy: revised classification using Scheimpflug tomography for preoperative assessment (Ophthalmology. 2019;2:195-204)
Authors: Deepali Singhal, Pranita Sahay, Ritu Nagpal, Prafulla K. Maharana
Journal: Ophthalmology (2019)
Distinct Genetic and Functional Traits of Human Intestinal Prevotella copri Strains Are Associated with Different Habitual Diets
Authors: Francesca De Filippis, Edoardo Pasolli, Adrian Tett, Sonia Tarallo, Alessio Naccarati, Maria De Angelis, Erasmo Neviani, Luca Cocolin, Marco Gobbetti, Nicola Segata, Danilo Ercolini
Journal: Cell Host & Microbe (2019)
World Health Organization‐defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management
Authors: Jason Gotlib
Journal: American Journal of Hematology (2015)

Disease overview : The eosinophilias encompass a broad range of non‐hematologic (secondary or reactive) and hematologic (primary, clonal) disorders with potential for end‐organ damage. Diagnosis : Hypereosinophilia has generally been defined as a peripheral blood eosinophil count greater than 1,500/mm 3 and may be associated with tissue damage. After exclusion of secondary causes of eosinophilia, diagnostic evaluation of primary eosinophilias relies on a combination of morphologic review of the blood and marrow, standard cytogenetics, fluorescent in situ ‐hybridization, flow immunocytometry, and T‐cell clonality assessment to detect histopathologic or clonal evidence for an acute or chronic myeloid or lymphoproliferative disorder. Risk stratification : Disease prognosis relies on identifying the subtype of eosinophilia. After evaluation of secondary causes of eosinophilia, the 2008 World Health Organization establishes a semi‐molecular classification scheme of disease subtypes including ‘myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA , PDGFRB , or FGFR1 ’, chronic eosinophilic leukemia, not otherwise specified, (CEL, NOS), lymphocyte‐variant hypereosinophilia, and idiopathic hypereosinophilic syndrome (HES), which is a diagnosis of exclusion. Risk‐adapted therapy : The goal of the therapy is to mitigate eosinophil‐mediated organ damage. For patients with milder forms of eosinophilia (e.g. &lt; 1,500/mm 3 ) without symptoms or signs of organ involvement, a watch and wait approach with close‐follow‐up may be undertaken. Identification of rearranged PDGFRA or PDGFRB is critical because of the exquisite responsiveness of these diseases to imatinib. Corticosteroids are first‐line therapy for patients with lymphocyte‐variant hypereosinophilia and HES. Hydroxyurea and interferon‐alpha have demonstrated efficacy as initial treatment and steroid‐refractory cases of HES. In addition to hydroxyurea, second line cytotoxic chemotherapy agents and hematopoietic cell transplant have been used for aggressive forms of HES and CEL with outcomes reported for limited numbers of patients. Although clinical trials have been performed with anti IL‐5 (mepolizumab) and anti‐CD52 (alemtuzumab) antibodies, their therapeutic role in primary eosinophilic diseases and HES has yet to be established. Am. J. Hematol. 90:1077–1089, 2015. © 2015 Wiley Periodicals, Inc.
Abstract P5-12-03: Withdrawn
Authors: M Wood, DK Seisler, M-K Hsieh, D Kontos, A Ambaye, H Le-Petross, S-H Jung, H Liu, P Zekan, L Cardinal, J Charlamb, LX Wang, GW Unzeitig, J Garber, J Marshall
Journal: Cancer Research (2018)

Abstract This abstract was withdrawn by the authors.
Progress Toward Poliomyelitis Eradication — Pakistan, January 2014–September 2015
Authors: Noha H. Farag, Mufti Zubair Wadood, Rana Muhammad Safdar, Nabil Ahmed, Sabrine Hamdi, Rudolph H. Tangermann, Derek Ehrhardt
Journal: MMWR Morbidity and Mortality Weekly Report (2015)

Since Nigeria reported its last case of wild poliovirus type 1 (WPV1) in July 2014, Pakistan and Afghanistan remain the only two countries where WPV transmission has never been interrupted. This report describes actions taken and progress achieved toward polio eradication in Pakistan during January 2014-September 2015 and updates previous reports. A total of 38 WPV1 cases were reported in Pakistan during January-September 2015, compared with 243 during the same period in 2014 (an 84% decline). Among WPV1 cases reported in 2015, 32 (84%) occurred in children aged <36 months, nine (32%) of whom had never received oral poliovirus vaccine (OPV). Twenty-six (68%) of the 38 reported cases occurred in the Federally Administered Tribal Areas (FATA) and Khyber Pakhtunkhwa (KPK) Province. During January-September 2015, WPV1 was detected in 20% (64 of 325) of environmental samples collected, compared with 34% (98 of 294) of samples collected during the same period in 2014. The quality and scope of polio eradication activities improved considerably following the establishment of a national Emergency Operations Center, which coordinated polio eradication partners' activities. All activities are following a National Polio Eradication Emergency Action Plan that includes a rigorous action plan for the polio low transmission season (January-April). The presence of WPV1 in environmental samples in areas where no polio cases are detected highlights the need to improve surveillance for acute flaccid paralysis (AFP). Focused efforts to close remaining immunity gaps by locating, tracking, and vaccinating continually missed children and improving coverage with OPV through the routine vaccination program are needed to stop WPV transmission in Pakistan.
Utility of Cricoid Pressure
Authors: Cheuk-Kwan Sun, Ying-Jen Chang, Kuo-Chuan Hung
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Young High Risk Patients with MYC/BCL2 Double Hit Lymphoma, BCL2+ and/or Germinal Centre B-Cell like Diffuse Large B-Cell Lymphoma Benefit from Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis: Analysis of Data from the Nordic Lymphoma Group CRY-04 and Chic Trials
Authors: Sirpa Leppa, Judit Jørgensen, Leo Meriranta, Klaus Beiske, Jan M.A. Delabie, Elisabeth Ralfkiaer, Signe Spetalen, Marja-Liisa Karjalainen-Lindsberg, Harald Holte
Journal: Blood (2018)
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
Authors: Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat, Sara M. Tolaney, Steven J. Isakoff, Jennifer R. Diamond, Joyce O’Shaughnessy, Rebecca L. Moroose, Alessandro D. Santin, Vandana G. Abramson, Nikita C. Shah, Hope S. Rugo, David M. Goldenberg, Ala M. Sweidan, Robert Iannone, Sarah Washkowitz, Robert M. Sharkey, William A. Wegener, Kevin Kalinsky
Journal: New England Journal of Medicine (2019)

Standard chemotherapy is associated with low response rates and short progression-free survival among patients with pretreated metastatic triple-negative breast cancer. Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjugated to the antibody by a cleavable linker. Sacituzumab govitecan-hziy enables delivery of high concentrations of SN-38 to tumors.
Abstract P4-12-21: Trastuzumab cardiac toxicity and HER2 polymorphism: A case-control study
Authors: A Mailliez, A Dumont, J Bonneterre
Journal: Cancer Research (2013)

Abstract Background: Gene polymorphisms of HER2 have been identified. Their impact on the risk of breast cancer, the response and the toxicity of anti HER2 treatments have been studied. According to a small report of Beauclair (2007), the polymorphism at codon 655 of the HER2 gene may represent a risk factor for cardiotoxicity induced by Trastuzumab (T). In this study, we evaluated the incidence of the Val655Ile polymorphism in (neo)adjuvant breast cancer patients (pts) with cardiac toxicity and in matched patients without cardiac toxicity. Methods: 40 HER2 positive breast cancer pts treated between 2008 and 2011 by (neo)adjuvant sequential chemotherapy plus T developed a cardiac toxicity. Definition of cardiac toxicity was a 10% absolute decrease in LVEF (Left Ventricular Ejection Fraction) or a decrease in LVEF to a threshold value of &amp;lt;50%. 84 pts without cardiac toxicity were matched according to age, received dose of anthracyclin and T, BMI and cardiac risk factors. Polymorphism of Her2 gene in codon 655 was searched by PCR on lymphocyte DNA from blood samples in this population and in the control group. Genomic DNA was extracted from EDTA blood samples (300ml) on the MagNa Pure Compact instrument. The HER2 Ile655Val (rs1163201) polymorphism was detected by sequencing using a 3730 DNA Analyser. Results: In the cardiac toxicity group 2,5% (1 patient) presented a genotype Val/Val at HER2 codon 655, 40% (16) were heterozygous (Ile) and 57,5% (23) had the wild type. In the control population, the incidence was respectively 3,6% (3 pts), 36,9% (31) and 59,5% (50). No differences were found between the both groups (p = 0,91). Conclusions: The incidence of mutated, heterogeneous and wild type genotype was similar to the literature. We could not confirm the Val allele at HER2 codon 655 as a risk factor of cardiotoxicity. HER2 polymorphism cannot be used in clinical practice to predict the risk of cardiac toxicity of T. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-12-21.
10-Year Heart Failure Outcomes From Nurse-Driven Clinics in Rural Sub-Saharan Africa
Authors: Lauren A. Eberly, Emmanuel Rusingiza, Paul H. Park, Gedeon Ngoga, Symaque Dusabeyezu, Francis Mutabazi, Cyprien Gahamanyi, Evariste Ntaganda, Gene F. Kwan, Gene Bukhman
Journal: Journal of the American College of Cardiology (2019)
Nut Consumption in Relation to Cardiovascular Disease Incidence and Mortality Among Patients With Diabetes Mellitus
Authors: Gang Liu, Marta Guasch-Ferré, Yang Hu, Yanping Li, Frank B. Hu, Eric B. Rimm, JoAnn E. Manson, Kathryn M. Rexrode, Qi Sun
Journal: Circulation Research (2019)

Rationale: The evidence regarding the potential health benefits of nut consumption among individuals with type 2 diabetes mellitus is limited. Objective: To examine intake of total and specific types of nuts, including tree nuts and peanuts, in relation to subsequent risk of cardiovascular disease (CVD), including coronary heart disease and stroke, and all-cause and cause-specific mortality among individuals with diabetes mellitus. Methods and Results: This prospective analysis included 16 217 men and women with diabetes mellitus at baseline or diagnosed during follow-up (Nurses’ Health Study: 1980–2014, Health Professionals Follow-Up Study: 1986–2014). Nut consumption was assessed using a validated food frequency questionnaire and updated every 2 to 4 years. During 223 682 and 254 923 person-years of follow-up, there were 3336 incident CVD cases and 5682 deaths, respectively. Higher total nut consumption was associated with a lower risk of CVD incidence and mortality. The multivariate-adjusted hazard ratios (95% CIs) for participants who consumed 5 or more servings of total nuts per week (1 serving=28 g), compared with those who consumed &lt;1 serving per month, were 0.83 (0.71–0.98; P trend=0.01) for total CVD incidence, 0.80 (0.67–0.96; P trend=0.005) for coronary heart disease incidence, 0.66 (0.52–0.84; P trend &lt;0.001) for CVD mortality, and 0.69 (0.61–0.77; P trend &lt;0.001) for all-cause mortality. Total nut consumption was not significantly associated with risk of stroke incidence or cancer mortality. For specific types of nuts, higher tree nut consumption was associated with lower risk of total CVD, coronary heart disease incidence, and mortality because of CVD, cancer, and all causes, whereas peanut consumption was associated with lower all-cause mortality only (all P trend &lt;0.001). In addition, compared with participants who did not change the consumption of total nuts from pre- to post-diabetes mellitus diagnosis, participants who increased consumption of total nuts after diabetes mellitus diagnosis had an 11% lower risk of CVD, a 15% lower coronary heart disease risk, a 25% lower CVD mortality, and a 27% lower all-cause mortality. The associations persisted in subgroup analyses stratified by sex/cohort, body mass index at diabetes mellitus diagnosis, smoking status, diabetes mellitus duration, nut consumption before diabetes mellitus diagnosis, or diet quality. Conclusions: Higher consumption of nuts, especially tree nuts, is associated with lower CVD incidence and mortality among participants with diabetes mellitus. These data provide novel evidence that supports the recommendation of incorporating nuts into healthy dietary patterns for the prevention of CVD complications and premature deaths among individuals with diabetes mellitus.
Association of Duration of Surgery With Postoperative Delirium Among Patients Receiving Hip Fracture Repair
Authors: Bheeshma Ravi, Daniel Pincus, Stephen Choi, Richard Jenkinson, David N. Wasserstein, Donald A. Redelmeier
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Postoperative delirium in older adults receiving hip fracture surgery is associated with morbidity and increased health care costs, yet little is known of potential modifiable factors that may help limit the risks. <h3>Objective</h3> To use population-wide individual-level data on the duration of hip fracture surgery to determine whether prolonged surgical times and type of anesthesia are associated with an increased risk of postoperative delirium. <h3>Design, Setting, and Participants</h3> This retrospective population-based cohort study analyzed patients aged 65 years and older receiving hip fracture surgery between April 1, 2009, and March 30, 2017, at 80 hospitals in Ontario, Canada. Generalized estimated equations with logistic regression analysis were used to determine the relationship between procedure duration, type of anesthesia, and the occurrence of postoperative delirium. Restricted cubic splines were also generated to visualize this relationship. Data analysis was conducted from July to October 2018, revision in January 2019. <h3>Exposure</h3> Surgery duration, measured as the total time in the operating room. <h3>Main Outcomes and Measures</h3> A diagnosis of postoperative delirium during hospitalization. <h3>Results</h3> Among 68 131 patients with surgically managed hip fracture (median [interquartile range] age, 84 [78-89] years; 72% women) identified, 7150 patients experienced postoperative delirium. In total, 26 853 patients (39.4%) received general anesthesia. Receiving general anesthesia was associated with a slightly higher rate of postoperative delirium compared with not receiving general anesthesia (2943 [11.0%] vs 4207 [10.2%];<i>P</i> = .001). The risk for delirium increased with increased surgical duration—every 30-minute increase in the duration of surgery was associated with a 6% increase in the risk for delirium (adjusted odds ratio, 1.06; 95% CI, 1.03-1.08;<i>P</i> &lt; .001). Prolonged surgical duration was associated with a higher incidence of postoperative delirium, and the risk was higher was in patients who had received general anesthesia (adjusted odds ratio, 1.08; 95% CI, 1.04-1.12;<i>P</i> &lt; .001) than in those patients who did not receive GA (adjusted odds ratio, 1.04; 95% CI, 1.01-1.08;<i>P</i> = .01). <h3>Conclusions and Relevance</h3> Among older adults receiving hip fracture surgery, both an increased duration of surgery and receiving a general anesthetic were associated with an increased risk for postoperative delirium.
SP0131 How does Anatomy Help to Learn Ultrasound?
Authors: I. Moller
Journal: Annals of the Rheumatic Diseases (2013)

<h3></h3> Gross anatomic study is clearly fundamental in the understanding of the ultrasound image and the term "sonoanatomy" has been applied to this convergence. "Sonoanatomy"also implies a different and dynamic way of exploring the superficial musculoskeletal and neurovascular structures and their relationships. The popularity of "sonoanatomy" courses among musculoskeletal practitioners of ultrasound is evidence of their desire to enhance their level of professional excellence in this area. In the very near future, ultrasound will become, not only an important educational component in the formation of medical practitioners, but will find important applications in the study of human anatomy itself. These programs are already receiving attention in a number of institutions. <h3>Disclosure of Interest</h3> None Declared